Afuco™ Anti-CTLA4 ADCC Therapeutic Antibody (Ticilimumab (= Tremelimumab)), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CTLA4. Tremelimumab (formerly ticilimumab, CP-675,206) is a fully human IgG2 monoclonal antibody, undergoing human trials for the treatment of cancer.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-206 |
| Pricing | Inquiry |
| Host | Human |
| Target | CTLA4 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | IF, IP, Neut, FuncS, ELISA |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |